Nuclomedone - Beijing Tide Pharmaceutical

Drug Profile

Nuclomedone - Beijing Tide Pharmaceutical

Alternative Names: DRP-043; NSL 043; SD-118; TEI 3096; TI 31

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teijin
  • Developer Beijing Tide Pharmaceutical; Teijin
  • Class Antirheumatics; Small molecules; Thiazoles
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Neuropathic pain
  • Discontinued Rheumatic disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain in China (PO, Capsule)
  • 13 Aug 2012 Beijing Tide Pharma acquires nuclomedone assets from Sosei Co. Ltd
  • 06 Sep 2011 No development reported - Phase-I for Neuropathic pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top